Effect	O
of	O
thalidomide	O
affecting	O
VEGF	O
secretion	O
,	O
cell	B-Cell
migration	O
,	O
adhesion	O
and	O
capillary	B-Tissue
tube	I-Tissue
formation	O
of	O
human	O
endothelial	B-Cell
EA	I-Cell
.	I-Cell
hy	I-Cell
926	I-Cell
cells	I-Cell
.	O

Angiogenesis	O
,	O
new	O
blood	B-Multi-tissue_structure
vessel	I-Multi-tissue_structure
formation	O
,	O
is	O
a	O
multistep	O
process	O
,	O
precisely	O
regulated	O
by	O
pro	O
-	O
angiogenic	O
cytokines	O
,	O
which	O
stimulate	O
endothelial	B-Cell
cells	I-Cell
to	O
migrate	O
,	O
proliferate	O
and	O
differentiate	O
to	O
form	O
new	O
capillary	B-Tissue
microvessels	I-Tissue
.	O

Excessive	O
vascular	B-Multi-tissue_structure
development	O
and	O
blood	B-Multi-tissue_structure
vessel	I-Multi-tissue_structure
remodeling	O
appears	O
in	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
diabetic	O
retinopathy	O
and	O
solid	B-Cancer
tumors	I-Cancer
formation	O
.	O

Thalidomide	O
[	O
alpha	O
-	O
(	O
N	O
-	O
phthalimido	O
)	O
-	O
glutarimide	O
]	O
is	O
known	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
angiogenesis	O
,	O
but	O
the	O
mechanism	O
of	O
its	O
inhibitory	O
action	O
remains	O
unclear	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
potential	O
influence	O
of	O
thalidomide	O
on	O
the	O
several	O
steps	O
of	O
angiogenesis	O
,	O
using	O
in	O
vitro	O
models	O
.	O

We	O
have	O
evaluated	O
the	O
effect	O
of	O
thalidomide	O
on	O
VEGF	O
secretion	O
,	O
cell	B-Cell
migration	O
,	O
adhesion	O
as	O
well	O
as	O
in	O
capillary	B-Tissue
formation	O
of	O
human	O
endothelial	B-Cell
cell	I-Cell
line	I-Cell
EA	I-Cell
.	I-Cell
hy	I-Cell
926	I-Cell
.	O

Thalidomide	O
at	O
the	O
concentrations	O
of	O
0	O
.	O
01	O
microM	O
and	O
10	O
microM	O
inhibited	O
VEGF	O
secretion	O
into	O
supernatants	B-Organism_substance
,	O
decreased	O
the	O
number	O
of	O
formed	O
capillary	B-Tissue
tubes	I-Tissue
and	O
increased	O
cell	B-Cell
adhesion	O
to	O
collagen	O
.	O

Administration	O
of	O
thalidomide	O
at	O
the	O
concentration	O
of	O
0	O
.	O
01	O
microM	O
increased	O
cell	B-Cell
migration	O
,	O
while	O
at	O
10	O
microM	O
,	O
it	O
decreased	O
cell	B-Cell
migration	O
.	O

Thalidomide	O
in	O
concentrations	O
from	O
0	O
.	O
1	O
microM	O
to	O
10	O
microM	O
did	O
not	O
change	O
cell	B-Cell
proliferation	O
of	O
72	O
-	O
h	O
cell	B-Cell
cultures	I-Cell
.	O

We	O
conclude	O
that	O
anti	O
-	O
angiogenic	O
action	O
of	O
thalidomide	O
is	O
due	O
to	O
direct	O
inhibitory	O
action	O
on	O
VEGF	O
secretion	O
and	O
capillary	B-Tissue
microvessel	I-Tissue
formation	O
as	O
well	O
as	O
immunomodulatory	O
influence	O
on	O
EA	B-Cell
.	I-Cell
hy	I-Cell
926	I-Cell
cells	I-Cell
migration	O
and	O
adhesion	O
.	O

